Zhangya Pu

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy”.

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.01.26.525680

N/A

0.165DataRank · unranked

2 citations

Zohreh Amoozgar, Xin Liu, Shuichi Aoki, Zelong Liu, Sarah M. Shin +17 more

Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy

Nature Communications(2022)10.1038/s41467-022-28279-8

N/A

0DataRank · unranked

261 citations

Jiang Chen, Hui Zhou, Xiaodong Zeng, Zhiping Ruan, Zhangya Pu +9 more

Inflammasome targeting with an NLRP3 agonist therapy is feasible but ineffective in murine hepatocellular carcinoma models with liver damage

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.06.23.497362

N/A

0DataRank · unranked

0 citations

Zelong Liu, Chen Jiang, Koetsu Inoue, Zhiping Ruan, Lingling Zhu +5 more

Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Cancer Immunology Research(2024)10.1158/2326-6066.cir-23-0486

N/A

0DataRank · unranked

28 citations

Zohreh Amoozgar, Xin Liu, Shuichi Aoki, Zelong Liu, Sarah M. Shin +20 more